Pet Cancer Therapeutics Market Analysis

Pet Cancer Therapeutics Market Analysis

To get key market trends

  Download Free Sample

Based on species, the global market is segmented into dogs, cats and other species. The dogs segment dominated the market and was valued at USD 402 million in 2024.
 

• The prominence of the dog segment is attributed to the higher incidence of cancer in dogs compared to other pets.
   
• As companion animals, dogs are more frequently diagnosed with cancers such as lymphoma, osteosarcoma, and mammary tumors, leading to an increased demand for therapeutic treatments.
   
• For instance, according to the Veterinary Cancer Society, cancer is the leading cause of death in 47% of dogs, particularly those over the age of ten. This statistic highlights the growing prevalence of cancer in older dogs, underscoring the increasing demand for cancer treatments. This growing need, especially in the aging dog population, is expected to significantly boost the market.
   
• Additionally, advancements in veterinary oncology, including more effective treatments and early detection techniques, have driven the growth of this segment.
   
• Furthermore, the growing awareness among pet owners about cancer in dogs, along with the availability of specialized therapies, significantly contributes to the dominance of the dog segment in this market.
   
• Lymphoma, a common cancer in dogs, has spurred research and drug approvals, such as the U.S. FDA’s 2021 approval of Tanovea (rabacfosadine injection). Additionally, ongoing clinical trials, such as Calviri, Inc.’s 2022 Vaccine Against Canine Cancer Study (VACCS) involving 800 dogs, highlight expanding awareness and therapeutic opportunities in the canine cancer segment for the forecast period.
   

Based on the therapy, the global pet cancer therapeutics market is segmented into chemotherapy, immunotherapy, targeted therapy, and combination therapy. The chemotherapy segment accounted for the highest market share of 62.1% in 2024.
 

• Chemotherapy effectively targets and kills cancer cells or inhibits their growth, making it a standard modality for various cancers, including lymphoma and mast cell tumors.
   
• As reported in several studies, the effectiveness of chemotherapy is highlighted by its ability to achieve remission in over 80% of cases, particularly for conditions like lymphoma, which are prevalent in dogs.
   
• As the market continues to grow, driven by increasing pet ownership and awareness of animal health, chemotherapy remains a cornerstone in veterinary oncology, providing vital treatment options for affected pets.
   

Based on the route of administration, the global pet cancer therapeutics market is segmented into oral and injection. The injection segment dominated the market in 2024 and is anticipated to reach USD 789 million by 2034.
 

• The preference for injections stems from their effectiveness in delivering cancer treatments directly into the bloodstream or at the tumor site.
   
• Injectable therapies, such as chemotherapy agents and immunotherapies, provide rapid absorption and targeted effects, making them particularly effective for treating a range of cancers in pets.
   
• These treatments are favored for their precision and superior management of side effects.
   
• With ongoing advancements in injectable formulations, the demand for injectable cancer therapeutics in veterinary care is anticipated to remain robust, further propelling the growth and dominance of this segment in the market.
   

Based on cancer type, the global pet cancer therapeutics market is segmented into lymphoma, mast cell cancer, melanoma, mammary and squamous cell cancer, and other cancer types. The mast cell cancer segment is expected to grow at a 9.4% CAGR over the analysis period.
 

• The prominence of the mast cell cancer segment is attributed to the high prevalence of mast cell tumors in dogs, particularly in certain breeds like Boxers, Bulldogs, and Retrievers.
   
• Mast cell tumors are among the most common skin cancers in pets, and their aggressive nature often necessitates immediate and specialized treatment.
   
• For instance, according to the Morris Animal Foundation, mast cell tumors account for 16% to 21% of all skin tumors in pets. These tumors can vary in appearance and behavior, ranging from slow-growing, isolated masses to ulcerated, itchy, and diffuse lesions.
   
• Their prevalence, along with the potential for malignancy and complications, has contributed to the dominance of the mast cell cancer segment in the market.
   

In 2024, the U.S. held a significant position in the North American pet cancer therapeutics market and projected to dominate throughout the forecast period with a CAGR of 9.3%.
 

• The U.S. prominence was driven by its advanced veterinary healthcare infrastructure, high pet ownership rates, and increasing awareness of cancer treatments for pets.
   
• The country invests heavily in veterinary oncology, benefiting from cutting-edge technologies, research, and a broad array of treatment options, including chemotherapy, immunotherapy, and targeted therapies.
   
• Furthermore, the rising incidence of pet cancers, particularly among aging pets, further fuels demand for these therapeutics.
   
• Additionally, the presence of leading veterinary pharmaceutical companies and animal health clinics further solidified the U.S.'s role as the key driver of market growth in North America.
   

The pet cancer therapeutics market in Germany is estimated to grow at significant growth rate over the next few years.
 

• Germany's growth in the market is driven by factors such as increasing awareness of pet health, advancements in veterinary oncology, and a rising demand for specialized cancer treatments.
   
• For instance, according to Der Deutsche Heimtiermarkt in 2021, 47% of German households owned pets, with 34.7 million dogs, cats, small animals, and birds. The growing pet ownership has led to heightened awareness of pet health, resulting in increased spending on veterinary care and cancer therapeutics.
   
• As cancer is a leading cause of death in pets, this trend is expected to boost demand for cancer diagnostics and treatments, with ongoing research further supporting market growth in Germany.
   

China held the prominent position in the Asia Pacific pet cancer therapeutics market during the analysis period.
 

• China’s growth was driven by the increasing incidence of pet cancer, elevated awareness among pet owners and veterinarians regarding effective treatments, and advancements in veterinary medicine.
   
• The country's robust biotechnology sector and supportive government policies further enhance its attractiveness for therapeutic manufacturing in veterinary oncology.
   
• In addition, as domestic companies innovate and produce affordable cancer treatments, China is also positioned as a key exporter of veterinary therapeutics, contributing to its influence in the animal healthcare market, which was valued at USD 186.1 billion in 2023.
   

Brazil pet cancer therapeutics market is anticipated to witness high growth over the analysis timeframe in Latin America.
 

• Increasing pet ownership, coupled with rising awareness of cancer treatment options, is driving demand for advanced veterinary care in the country.
   
• In addition, the growing recognition of the specialized oncology treatments for pets, such as chemotherapy, immunotherapy, and targeted therapies, is contributing to the market’s expansion.
   
• Additionally, Brazil's expanding veterinary healthcare infrastructure, along with the availability of more effective cancer therapeutics, is likely to enhance access to these treatments.
   
• Therefore, the aforementioned factors witnessed the Brazil’s prominence in the Latin America market.
   

Saudi Arabia is anticipated to grow in the Middle East and African pet cancer therapeutics market.

• Saudi Arabia's increasing pet ownership, particularly among affluent urban populations, is driving demand for advanced veterinary care.
   
• As awareness of pet health and cancer treatment options rises, more pet owners are seeking specialized cancer therapies such as chemotherapy and immunotherapy.
   
• Additionally, Saudi Arabia's expanding veterinary healthcare infrastructure, along with investments in research and development, are improving access to cutting-edge treatments.
   
• These developments position Saudi Arabia as a key market in the region for pet cancer therapeutics over the forecast period.